302 related articles for article (PubMed ID: 23106273)
41. Cyclic di-GMP regulates Mycobacterium tuberculosis resistance to ethionamide.
Zhang HN; Xu ZW; Jiang HW; Wu FL; He X; Liu Y; Guo SJ; Li Y; Bi LJ; Deng JY; Zhang XE; Tao SC
Sci Rep; 2017 Jul; 7(1):5860. PubMed ID: 28725053
[TBL] [Abstract][Full Text] [Related]
42. Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences.
de Kantor IN; Barrera L
Medicina (B Aires); 2007; 67(3):231-7. PubMed ID: 17628909
[TBL] [Abstract][Full Text] [Related]
43. In vitro chemotherapeutic combinations against isoniazid-resistant Mycobacterium tuberculosis and Mycobacterium fortuitum.
Goldstein E; Eagle MC; LaCasse ML
Appl Microbiol; 1971 Sep; 22(3):329-33. PubMed ID: 4330314
[TBL] [Abstract][Full Text] [Related]
44. Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.
Fillion A; Aubry A; Brossier F; Chauffour A; Jarlier V; Veziris N
Antimicrob Agents Chemother; 2013 Sep; 57(9):4496-500. PubMed ID: 23836169
[TBL] [Abstract][Full Text] [Related]
45. Antibiotic resistance mechanisms in M. tuberculosis: an update.
Nguyen L
Arch Toxicol; 2016 Jul; 90(7):1585-604. PubMed ID: 27161440
[TBL] [Abstract][Full Text] [Related]
46. Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities.
Vilchèze C; Jacobs WR
Microbiol Spectr; 2014 Aug; 2(4):MGM2-0014-2013. PubMed ID: 26104204
[TBL] [Abstract][Full Text] [Related]
47. Intragenic Distribution of IS
Antoine R; Gaudin C; Hartkoorn RC
Microbiol Spectr; 2021 Sep; 9(1):e0001921. PubMed ID: 34287057
[TBL] [Abstract][Full Text] [Related]
48. Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates.
Bakuła Z; Napiórkowska A; Kamiński M; Augustynowicz-Kopeć E; Zwolska Z; Bielecki J; Jagielski T
J Microbiol Immunol Infect; 2016 Jun; 49(3):439-44. PubMed ID: 26117528
[TBL] [Abstract][Full Text] [Related]
49. Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis.
Bollela VR; Namburete EI; Feliciano CS; Macheque D; Harrison LH; Caminero JA
Int J Tuberc Lung Dis; 2016 Aug; 20(8):1099-104. PubMed ID: 27393546
[TBL] [Abstract][Full Text] [Related]
50. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates.
Morlock GP; Metchock B; Sikes D; Crawford JT; Cooksey RC
Antimicrob Agents Chemother; 2003 Dec; 47(12):3799-805. PubMed ID: 14638486
[TBL] [Abstract][Full Text] [Related]
51. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis.
DeBarber AE; Mdluli K; Bosman M; Bekker LG; Barry CE
Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9677-82. PubMed ID: 10944230
[TBL] [Abstract][Full Text] [Related]
52. A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters.
Nikiforov PO; Surade S; Blaszczyk M; Delorme V; Brodin P; Baulard AR; Blundell TL; Abell C
Org Biomol Chem; 2016 Feb; 14(7):2318-26. PubMed ID: 26806381
[TBL] [Abstract][Full Text] [Related]
53. Phenotypic low-level isoniazid resistance as a marker to predict ethionamide resistance in
Qamar S; Farooqi JQ; Jabeen K; Hasan R
Int J Mycobacteriol; 2017; 6(2):167-170. PubMed ID: 28559519
[TBL] [Abstract][Full Text] [Related]
54. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis.
Cavalieri SJ; Biehle JR; Sanders WE
Antimicrob Agents Chemother; 1995 Jul; 39(7):1542-5. PubMed ID: 7492101
[TBL] [Abstract][Full Text] [Related]
55. A review of the use of ethionamide and prothionamide in childhood tuberculosis.
Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS
Tuberculosis (Edinb); 2016 Mar; 97():126-36. PubMed ID: 26586647
[TBL] [Abstract][Full Text] [Related]
56. The small-molecule SMARt751 reverses
Flipo M; Frita R; Bourotte M; Martínez-Martínez MS; Boesche M; Boyle GW; Derimanov G; Drewes G; Gamallo P; Ghidelli-Disse S; Gresham S; Jiménez E; de Mercado J; Pérez-Herrán E; Porras-De Francisco E; Rullas J; Casado P; Leroux F; Piveteau C; Kiass M; Mathys V; Soetaert K; Megalizzi V; Tanina A; Wintjens R; Antoine R; Brodin P; Delorme V; Moune M; Djaout K; Slupek S; Kemmer C; Gitzinger M; Ballell L; Mendoza-Losana A; Lociuro S; Deprez B; Barros-Aguirre D; Remuiñán MJ; Willand N; Baulard AR
Sci Transl Med; 2022 May; 14(643):eaaz6280. PubMed ID: 35507672
[TBL] [Abstract][Full Text] [Related]
57. Antimycobacterial activity of usnic acid against resistant and susceptible strains of Mycobacterium tuberculosis and non-tuberculous mycobacteria.
Ramos DF; Almeida da Silva PE
Pharm Biol; 2010 Mar; 48(3):260-3. PubMed ID: 20645810
[TBL] [Abstract][Full Text] [Related]
58. Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase.
Gerum AB; Ulmer JE; Jacobus DP; Jensen NP; Sherman DR; Sibley CH
Antimicrob Agents Chemother; 2002 Nov; 46(11):3362-9. PubMed ID: 12384337
[TBL] [Abstract][Full Text] [Related]
59. Fluoroquinolone-resistant tuberculosis at a medical centre in Taiwan, 2005-10.
Lai CC; Tan CK; Huang YT; Liao CH; Hsueh PR
J Antimicrob Chemother; 2011 Oct; 66(10):2437-8. PubMed ID: 21798881
[No Abstract] [Full Text] [Related]
60. Mechanisms of drug resistance in Mycobacterium tuberculosis and current status of rapid molecular diagnostic testing.
Laurenzo D; Mousa SA
Acta Trop; 2011 Jul; 119(1):5-10. PubMed ID: 21515239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
